Workman P, Twentyman P R, Lee F Y, Walton M I
Biochem Pharmacol. 1983 Mar 1;32(5):857-64. doi: 10.1016/0006-2952(83)90588-9.
The nitroimidazole misonidazole (MISO) and related compounds have been shown to enhance the response of tumours to cytotoxic agents, and often to improve their therapeutic indices. Previous experiments suggested inhibition of cytotoxic drug metabolism as a mechanism. We have now investigated the effects of MISO and related compounds on drug metabolism in mice, and the results can be summarised as follows. (1) MISO and related compounds inhibit drug-metabolising enzymes, as measured by pentobarbitone sleep-time and zoxazolamine paralysis-time. (2) Enzyme inhibition is primarily dependent on lipophilicity, with maximum inhibition exhibited by the most active chemosensitizers. (3) MISO significantly slowed the clearance of pentobarbitone, aminopyrine and the cytotoxic agent chlorambucil, but had no effect on renal function or protein binding. These data support the view that inhibition of cytotoxic drug metabolism may be an important factor in chemosensitization.
硝基咪唑类药物米索硝唑(MISO)及相关化合物已被证明可增强肿瘤对细胞毒性药物的反应,并常常能改善其治疗指数。先前的实验表明,抑制细胞毒性药物代谢是一种作用机制。我们现在研究了米索硝唑及相关化合物对小鼠药物代谢的影响,结果总结如下:(1)通过戊巴比妥睡眠时间和唑沙宗麻痹时间测定,米索硝唑及相关化合物可抑制药物代谢酶。(2)酶抑制主要取决于亲脂性,最具活性的化学增敏剂表现出最大抑制作用。(3)米索硝唑显著减慢了戊巴比妥、氨基比林和细胞毒性药物苯丁酸氮芥的清除,但对肾功能或蛋白结合无影响。这些数据支持了以下观点,即抑制细胞毒性药物代谢可能是化学增敏中的一个重要因素。